Sotorasib Is Not Effective in a KRAS-Mutated Patient With Brain Metastases From Lung Adenocarcinoma due to Multiple...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung adenocarcinoma is a significant cause of cancer-related mortality.
• Targeted therapies, such as sotorasib, have shown promise for specific mutations like KRAS G12C.
• Tumor heterogeneity and the presence of co-occurring mutations can influence treatment response.

Purpose of the Study:

• To investigate the molecular mechanisms underlying resistance to sotorasib in a patient with KRAS G12C-mutated lung adenocarcinoma.
• To identify potential genetic markers associated with primary or acquired resistance to targeted therapy.

Main Methods:

• Surgical resection of primary tumor and metastatic lesions.
• Oncomine Dx Target Test for KRAS G12C mutation detection in metastatic tissue.
• Cancer Genome Profiling (CGP) Test for comprehensive genomic analysis of the primary tumor.

Main Results:

• A patient with lung adenocarcinoma initially treated with lobectomy developed brain and liver metastases.
• KRAS G12C mutation was identified in metastatic tissue, but sotorasib treatment proved ineffective.
• Comprehensive genomic profiling revealed pre-existing p53 and BRCA2 mutations in the primary tumor.

Conclusions:

• The presence of co-occurring p53 and BRCA2 mutations in the primary tumor may confer intrinsic resistance to KRAS G12C-targeted therapy like sotorasib.
• Genomic profiling of the primary tumor is crucial for predicting response to targeted therapies.
• Understanding complex mutational landscapes is essential for optimizing lung cancer treatment strategies.